NO20030729L - Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister - Google Patents

Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister

Info

Publication number
NO20030729L
NO20030729L NO20030729A NO20030729A NO20030729L NO 20030729 L NO20030729 L NO 20030729L NO 20030729 A NO20030729 A NO 20030729A NO 20030729 A NO20030729 A NO 20030729A NO 20030729 L NO20030729 L NO 20030729L
Authority
NO
Norway
Prior art keywords
alkyl
unsubstituted
oxazolyl
substituted
acid derivatives
Prior art date
Application number
NO20030729A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030729D0 (no
Inventor
Dawn Alisa Brooks
Alexander Glenn Godfrey
Sarah Beth Jones
James Ray Mccarthy
Christopher John Rito
Jr Leonard Larry Winneroski
Yanping Xu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20030729D0 publication Critical patent/NO20030729D0/no
Publication of NO20030729L publication Critical patent/NO20030729L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
NO20030729A 2000-08-23 2003-02-14 Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister NO20030729L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22723400P 2000-08-23 2000-08-23
PCT/US2001/022616 WO2002016331A1 (en) 2000-08-23 2001-08-23 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists

Publications (2)

Publication Number Publication Date
NO20030729D0 NO20030729D0 (no) 2003-02-14
NO20030729L true NO20030729L (no) 2003-04-02

Family

ID=22852309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030729A NO20030729L (no) 2000-08-23 2003-02-14 Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister

Country Status (26)

Country Link
US (2) US6930120B2 (de)
EP (1) EP1313716B1 (de)
JP (1) JP2004506721A (de)
KR (1) KR20030027054A (de)
CN (1) CN1471517A (de)
AT (1) ATE361283T1 (de)
AU (1) AU2001284659A1 (de)
BR (1) BR0113409A (de)
CA (1) CA2418104A1 (de)
CY (1) CY1107679T1 (de)
CZ (1) CZ2003482A3 (de)
DE (1) DE60128239T2 (de)
DK (1) DK1313716T3 (de)
EA (1) EA200300286A1 (de)
EC (1) ECSP034504A (de)
ES (1) ES2286137T3 (de)
HU (1) HUP0300857A3 (de)
IL (1) IL154110A0 (de)
MX (1) MXPA03001558A (de)
NO (1) NO20030729L (de)
NZ (1) NZ523804A (de)
PL (1) PL360744A1 (de)
PT (1) PT1313716E (de)
SK (1) SK1872003A3 (de)
WO (1) WO2002016331A1 (de)
ZA (1) ZA200300570B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
ES2295200T3 (es) 2000-08-23 2008-04-16 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
ME01310B (me) * 2001-05-15 2011-10-10 Hoffmann La Roche Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa
KR100459917B1 (ko) * 2001-12-14 2004-12-03 (주)바이오뉴트리젠 페놀릭산 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
ATE372990T1 (de) 2002-07-03 2007-09-15 Hoffmann La Roche Oxazolderivat und deren verwendung als insulinsensibilisatoren
CN100475810C (zh) * 2002-08-30 2009-04-08 霍夫曼-拉罗奇有限公司 作为PPARα和PPARγ激动剂的新型2-芳基噻唑化合物
NZ537979A (en) 2002-09-12 2007-08-31 Hoffmann La Roche N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
ES2295692T3 (es) * 2002-11-08 2008-04-16 F. Hoffmann-La Roche Ag Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar.
MXPA05005445A (es) 2002-11-25 2005-08-26 Hoffmann La Roche Derivados de indolilo.
DE10308355A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JP4767850B2 (ja) 2003-08-20 2011-09-07 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド(glp)−1化合物またはメラノコルチン4受容体(mc4)アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
CN100398536C (zh) * 2003-08-20 2008-07-02 爱密斯菲尔科技公司 用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
US20080051418A1 (en) * 2004-11-26 2008-02-28 Tsuyoshi Maekawa Arylalkanoic Acid Derivative

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6062509A (en) 1994-12-23 2000-05-16 Hexcel Corporation Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports
DE69723680T9 (de) 1996-02-02 2004-11-04 Merck & Co., Inc. Antidiabetische mittel
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
IL128600A0 (en) * 1996-08-19 2000-01-31 Japan Tobacco Inc Propionic acid derivatives and pharmaceutical compositions containing them
JP4345230B2 (ja) 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
DK1206457T3 (da) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
ES2295200T3 (es) 2000-08-23 2008-04-16 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.

Also Published As

Publication number Publication date
ES2286137T3 (es) 2007-12-01
CZ2003482A3 (cs) 2003-05-14
BR0113409A (pt) 2003-07-01
EP1313716B1 (de) 2007-05-02
HUP0300857A3 (en) 2007-03-28
IL154110A0 (en) 2003-07-31
US20050245584A1 (en) 2005-11-03
US6930120B2 (en) 2005-08-16
CY1107679T1 (el) 2013-04-18
ECSP034504A (es) 2003-04-25
KR20030027054A (ko) 2003-04-03
DE60128239D1 (de) 2007-06-14
JP2004506721A (ja) 2004-03-04
ZA200300570B (en) 2004-04-21
AU2001284659A1 (en) 2002-03-04
HUP0300857A2 (hu) 2003-10-28
DE60128239T2 (de) 2008-01-10
NZ523804A (en) 2004-09-24
NO20030729D0 (no) 2003-02-14
US20040097590A1 (en) 2004-05-20
MXPA03001558A (es) 2003-06-06
US7345070B2 (en) 2008-03-18
CN1471517A (zh) 2004-01-28
ATE361283T1 (de) 2007-05-15
PT1313716E (pt) 2007-07-11
SK1872003A3 (en) 2003-07-01
DK1313716T3 (da) 2007-08-27
EA200300286A1 (ru) 2003-08-28
WO2002016331A1 (en) 2002-02-28
EP1313716A1 (de) 2003-05-28
PL360744A1 (en) 2004-09-20
CA2418104A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
NO20030729D0 (no) Oksazolyl-arylpropionsyrederivater og deres anvendelse som PPAR-agonister
AU2001284658A1 (en) Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
PT96255A (pt) Processo para a preparacao de novos derivados da 1-naftil-piperazina
SE423812B (sv) Forfarande for framstellning av terapeutiskt aktiva derivat av azetidin-2-karboxylsyra, prolin och pipekolinsyra
DK0540051T3 (da) Aromatiske amidinderivater og salte deraf
AR037898A1 (es) Compuesto de benzamida, uso de un compuesto de benzamida en la fabricacion de un medicamento, proceso para su preparacion y composicion farmaceutica que lo comprende
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
NO991957D0 (no) Nye benzotiofen, benzofuran og indolforbindelser, en fremgangsmÕte ved deres fremstilling og farmas°ytiske sammensetninger inneholdende dem
CO5640098A2 (es) Acidos biariloximetilaren-carboxilicos
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
WO2002028844A1 (en) Thiazole or oxazole derivatives
MXPA02011352A (es) Nuevos derivados de benzofurano.
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
DK0508740T3 (da) Thiazolidindionderivater, deres fremstilling og anvendelse.
SE8006365L (sv) Cyklohexankarboxylsyraderivat
NO994340L (no) FremgangsmÕte for fremstilling av 2-[[(2-pyridinyl)metyl]sulfinyl]-1H-benzimidazoler samt nye forbindelser til anvendelse for dette formÕl
NO994209L (no) Fremgangsmaate for fremstilling av 2-ÄÄ(2-pyridinyl)metylÜsulfinylÜ-1H-benzimidazoler og nye forbindelser til anvendelse for dette formaal
NO20051089L (no) Bredspektrede 2-amino-benzotiazol-sulfonamid-HIV-proteaseinhibitorer
NO20074738L (no) Aktivator for peroksisom-proliferator som aktiverer reseptor delta
DK1036793T3 (da) Fremgangsmåde til fremstilling af 2-alkyl-3-aminothiophenderivat og 3-aminothiophenderivat
DK1023898T3 (da) Cyanoindoler som serotonin-genoptagningsinhibitorer og som 5-HT2c-receptorligander
EP1535920A4 (de) Verfahren zur herstellung von 1,3-benzodioxol-2-spiro-cycloalkanderivaten
WO2007068815A3 (fr) Derives heterocycliques, leur preparation et leur application en therapeutique.
NO20003431D0 (no) Nye metalloproteaseinhibitorer, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application